Trial Profile
Rosiglitazone (Avandia) vs. placebo for androgren-dependent prostate cancer: a randomized, double-blind, placebo controlled phase III study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2005
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Nov 2005 New trial record.